ReviewSurgery today2006
Common fragile genes and digestive tract cancers.
Review in Surgery today, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Deletion at fragile sites is a common and early event in Barrett's esophagus.Molecular cancer research : MCR · 2010Article
- Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.International journal of clinical and experimental pathology · 2010Article
- Coordinate loss of fragile gene expression in pancreatobiliary cancers: correlations among markers and clinical features.Annals of surgical oncology · 2009Article
- Fhit tumor suppressor: guardian of the preneoplastic genome.Future oncology (London, England) · 2008Review
- The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.Journal of hepatology · 2008Article
- Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.Histopathology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FRA3B and FRA16D are the most sensitive common chromosomal fragile site loci in the human genome. Two tumor suppressor genes, the fragile histidine triad (FHIT) gene and the WW domain-containing oxidoreductase (WWOX), map to the common fragile sites, FRA3B and FRA16D, respectively. Interestingly, FHIT and WWOX have similarities: for example, they are both larger than 1 Mb and encompass fragile sites, they both show frequent allelic loss regions in various human cancers, they both span a region of homozygous deletion in multiple cancers, and they both frequently show aberrant transcripts. The development of human cancers, including digestive tract cancers, is strongly associated with exposure to environmental carcinogens. Common fragile sites are very sensitive to this type of exposure, and the resulting DNA damage leads to the inactivation of genes such as FHIT and WWOX. We present an overview of these two common fragile genes, namely FHIT/FRA3B and WWOX/FRA16D, in digestive tract cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.